Faecal Immunochemical Tests
The Faecal Immunochemical Test (FIT) is designed to detect small amounts of blood in stool samples using antibodies specific to human haemoglobin (NICE Guidelines, 2015) . There is evidence from clinical effectiveness studies to support that FIT is almost as twice as sensitive than the older guaiac method of faecal occult blood testing.
Current NICE recommendation: rule-in among low risk patients
Several lower gastrointestinal symptoms can suggest colorectal cancer, including rectal bleeding, a change in bowel habit, weight loss, anaemia, abdominal pain, and blood in stools (faeces). Sometimes, blood in stools is not visible (faecal occult blood) so tests are used to detect its presence.
Currently, NICE DG30 diagnostic guidance guideline recommends FIT to be used in primary care to assess people who are at a low risk of colorectal cancer (those who do not meet the suspected cancer pathway referral criteria outlined in NICE NG12 guideline) and help determine whether they should be referred for further investigations. In this context, patients who have haemoglobin higher than 10 micrograms Hb/g faeces would be referred to the Two Week Wait pathway for suspected cancer. In this scenario the cancer conversion rate (patients who have cancer out of all referrals) ranges between 6.1% and 8.9%. This means that the majority of patients who are refereed on an urgent pathway for suspected cancer do not have cancer.
Potential future use: rule-out among high risk patients
There is a growing interest to use FIT as a rule-out test among high risk patients as an alternative to colonoscopy. Evidence shows that if the same threshold (10 micrograms Hb/g) is used that there are a very low number of colorectal cancers missed which will be similar to colonoscopy. In other words, the negative predictive value is high, ranging from 99.8%-100% with minimal false negatives. Colonoscopy and FIT are not 100% accurate in ruling out significant bowel disease such as cancer.
The use of FIT in primary care as a rule-out test among high risk patients is currently being considered as an alternative to Two Week Wait referral to secondary care to reduce the pressure on colonoscopy services. FIT is a significantly cheaper compared to colonoscopy (£5 vs £300 respectively) However, if it is going to be implemented, it is important to understand how acceptable it would be in primary care.
This survey
We are interested in your thoughts about implementing FIT in primary care to rule out colorectal cancer among high risk symptomatic patients who would normally be referred to the Two Week Wait for suspected colorectal cancer. The following survey includes questions about your awareness of FIT in general, and your views on FIT as a rule out-test, implementation and your demographics.
